Literature DB >> 21428886

Targeted therapy in colorectal cancer: current status and future challenges.

A K Koutras1, I Starakis, U Kyriakopoulou, P Katsaounis, A Nikolakopoulos, H P Kalofonos.   

Abstract

Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab / panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21428886     DOI： 10.2174/092986711795471338

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  10 in total

1.  Identification and chromosomal localizations of signal transduction genes associated with human ovarian cancer metastasis.

Authors:  Zhu Xin; Xu Shenhua; Mou Hanzhou; Gu Linhui; Zhu Chihong; Liu Xianglin
Journal:  Med Oncol       Date:  2012-02-05       Impact factor: 3.064

Review 2.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

3.  Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome.

Authors:  K S Ramcharan; G Y H Lip; P S Stonelake; A D Blann
Journal:  Int J Colorectal Dis       Date:  2015-01-20       Impact factor: 2.571

4.  Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.

Authors:  Qi-Yin Chen; Yanxia Liu; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2011-08-31       Impact factor: 4.345

5.  EGFR soluble isoforms and their transcripts are expressed in meningiomas.

Authors:  Angélique Guillaudeau; Karine Durand; Barbara Bessette; Alain Chaunavel; Isabelle Pommepuy; Fabrice Projetti; Sandrine Robert; François Caire; Hélène Rabinovitch-Chable; François Labrousse
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

Review 6.  Emergence of TNIK inhibitors in cancer therapeutics.

Authors:  Tesshi Yamada; Mari Masuda
Journal:  Cancer Sci       Date:  2017-04-24       Impact factor: 6.716

7.  Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.

Authors:  K S Ramcharan; G Y H Lip; P S Stonelake; A D Blann
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640

8.  Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.

Authors:  Yonggang Wang; Felix H Shek; Kwong F Wong; Ling Xiao Liu; Xiao Qian Zhang; Yi Yuan; Ester Khin; Mei-Yu Hu; Jian Hua Wang; Ronnie T P Poon; Wanjin Hong; Nikki P Lee; John M Luk
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

9.  Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity.

Authors:  Qi-Yin Chen; Yanxia Liu; Weijing Cai; Hendrik Luesch
Journal:  J Med Chem       Date:  2014-03-24       Impact factor: 7.446

Review 10.  Perspective on the dynamics of cancer.

Authors:  Youcef Derbal
Journal:  Theor Biol Med Model       Date:  2017-10-03       Impact factor: 2.432
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.